Proactive Investors - Run By Investors For Investors

Cello Health Plc makes strong start to 2019 with good order book and new wins

Cello Health PLC (LON:CLL) chief executive Mark Scott discusses with Proactive London the group's results for the year to December 2018.

Cello Health's begun 2019 with good levels of forward bookings and has already landed a number of new business wins.

In 2018 the company reported headline profit before tax of £12.2mln, up 6.4% from the £11.4mln reported for 2017.

The group enjoyed strong cash flows in the second half of the year and ended 2018 with net funds of £6.3mln, up from £1.6mln a year earlier.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full CLL profile View Profile

Cello Health PLC Timeline

April 11 2019
Big Picture
March 22 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use